HUA MEDICINE-B (02552) Key Financial Indicators

3.440
-0.090-2.55%

Not Open Apr 24 16:05 CST

3.63BMarket Cap2.97P/E (TTM)

02552 Current Ratio

If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of HUA MEDICINE-B shows that the company's current ratio is 6.17, indicating healthy liquidity.

Currency: CNY

Cumulative Quarterly

02552 Quick Ratio

Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of HUA MEDICINE-B, the quick ratio is 5.59, indicating that the company can meet its short-term debt obligations.

Currency: CNY

Cumulative Quarterly

02552 Return on Equity (ROE)

Want to learn more about the financial health of HUA MEDICINE-B? The latest ROE figure is 253.08%, indicating that the company has stable profitability.

Currency: CNY

Cumulative Quarterly

02552 Return on Assets (ROA)

Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of HUA MEDICINE-B, the total asset return on investment (ROA) is 74.77%.

Currency: CNY

Cumulative Quarterly

02552 Gross Margin

Gross margin can provide insight into a company's pricing strategy and cost structure. Check HUA MEDICINE-B's latest financial report to see how their gross margin is doing - currently at 56.87%.

Currency: CNY

Cumulative Quarterly

02552 Net Margin

For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of HUA MEDICINE-B, the net profit margin is 224.44%, which is a good sign for its profitability.

Currency: CNY

Cumulative Quarterly

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"